- Home
- DSGN vs SBGI Comparison
DSGN vs SBGI Comparison
Compare DSGN & SBGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DSGN | SBGI |
|---|---|---|
| Founded | 2017 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Broadcasting |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 853.8M | 909.8M |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | DSGN | SBGI |
|---|---|---|
| Price | $10.75 | $12.69 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 7 |
| Target Price | ★ $21.71 | $17.57 |
| AVG Volume (30 Days) | ★ 507.9K | 448.5K |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 7.52% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,169,000,000.00 |
| Revenue This Year | N/A | $11.11 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.40 | $12.23 |
| 52 Week High | $17.25 | $17.88 |
Technical Indicators
Market Signals| Indicator | DSGN | SBGI |
|---|---|---|
| Relative Strength Index (RSI) | 39.66 | 45.17 |
| Support Level | $9.78 | $12.32 |
| Resistance Level | $11.18 | $14.50 |
| Average True Range (ATR) | 0.67 | 0.47 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 39.63 | 39.13 |
Price Performance
Historical ComparisonAbout DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
About SBGI Sinclair Inc.
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay TV distributors.